Agent Mechanism ClinicalTrials.gov Identifier  Principal Investigator N° of Patients Dose
GEFITINIB TKI EGFR Phase 2 Loehrer PJ, MD 26 (7TC) 250 mg daily
ERLOTINIB TKI EGFR NCT00369889 (plus Bevacizumab) (Phase 2) Loehrer PJ, MD 18 (7TC) 150 mg p.o.
NCT01306045 (Pilot Study) (Phase 2) Gula U, MD Recruiting 150 mg p.o.
CETUXIMAB EGFR antibody NCT01025089 (plus chemotherapy CAP) (Phase 2) ONGOING James Huang, MD Recruiting 250 mg/m2 weekly
IMATINIB TKI KIT, Bcr-Abl, and PDGFR Phase 2 Giaccone G, MD 7 (5 TC) 600 mg p.o. daily
Phase 1 Salter JT, MD 11 TC 600 mg p.o. daily
Phase 2 Palmieri G, MD 15 (3 TC) 400 mg p.o. daily
NCT00314873 (Phase 1) Loehrer PJ, MD 11 TC 600 mg qd q 21
SUNITINIB TKI VEGFR1-3, FMS-like TK3, c-KIT, PDGFR, FLT-3, RET-receptor and CSF1 NCT01621568 Phase 2 ONGOING Ragan A, MD Ragan A, MD 50 mg daily
SU14813 TKI VEGFR2, PDGFR, c-KIT, FLT-3 NCT00982267 (Phase 1) Pfizer 4 Escalating doses from 50 to 250 mg daily
MOTESANIB (AM 706) TKI KIT, VEGFR -1, -2, -3 and PDGFR NCT00093873 (Phase 1) Amgen 1 Escalating doses from 50 to 175 mg daily
SARACATINIB (AZD0530) Src non-receptor tyrosine kinase inhibitor NCT00718809 (Phase 2) P.Loeher, MD 21 (7TC) 175 mg daily
EVEROLIMUS mTOR inhibitor NCT01563354 (Phase 2) Novartis Recruiting 10 mg p.o. daily
CIXUTUMUMAB (IMC-A12) IGF-1R antibody NCT00965250 (Phase 2) Giaccone G, MD 49 (12TC) 20 mg/kg iv q21
FIGITUMUMAB (CP-751.871) Phase 2 Haluska P, MD 1 dose escalation from 3 to 20 mg/kg iv q21
BEVACIZUMAB VEGFR antibody NCT00369889 (Plus Erlotinib) (Phase 2) P. J Loehrer, MD 18 (7TC) 15 mg/kg iv q21
AFLIBERCEPT (AVE0005) TKI VEGFR-A, VEGFR-B and PIGF NCT00545246 with docetaxel (Phase 1) Sanofi 1 dose escalation 2, 4, 6, 7, 9 mg/kg iv
BELINOSTAT (PDX101 Pan-HDAC inhibitor NCT00589290 (Phase 2) Giaccone G, MD 41 (16 TC) 1000mg/m2 1-5 days q21
FR901228 (DP) and FLA HDAC inhibitor and CDK inhibitor NCT01100944 in combination with PAC (Phase 1/2) ONGOING Rajan A, MD 26 four dose levels and dose escalations
DECITABINE DNMT inhibitor (Phase 1) Stewart DJ 4 dose escalation 2,5-10 mg/m2 and 8,12,15,20 mg/m2
MILCICLIB MALEATE (PHA-848125AC CDK2, CDK1, CDK4 and TRKA Inhibitor NCT01011439 (Phase 2) ONGOING Weiss G, Besse B, Mazieres J, Novello S, Rajan A, Garassino MC, MD Recruiting TC 150 mg/daily
NCT01301391 (Phase 2) ONGOING Rajan A and Garassino, MD Recruiting Thymomas 150 mg daily 1-7
Octreotide-LAR NCT00990535 (HIDONET) (Phase 2) ONGOING Colao A, MD   30 mg sc/daily
Octreotide +/- prednisone NCT00003283 (Phase 2) Loehrer PJ, MD 38 (5 TC) 1.5 mg/daily subcut
Octreotide-LAR NCT00332969 (Phase 2) ONGOING NCT00332969 (Phase 2) ONGOING  Novartis 25 30 mg sc/daily
Table 1: Phase 1 and phase 2 trials with new targeted therapies in thymic malignancies.